Cancer News and Research

Latest Cancer News and Research

Varian and SSI sign reseller's agreement

Varian, Inc. announced today that Steady State Imaging (SSI) has signed a reseller's agreement with Varian, Inc. regarding SSI's new SWIFT Software for Varian's research MRI Systems. SWIFT is a novel MRI technology that advances existing MR techniques with the ability to silently image structures and tissues previously invisible to conventional MRI systems.

13 Nov 2009

African-Americans more likely to die from colorectal cancer than Caucasians, says new study

New research published in the November issue of the Journal of the American College of Surgeons shows that African-American patients with colorectal cancer are more likely to be diagnosed with advanced disease and are less likely to undergo surgical procedures compared with Caucasians, suggesting that improvements in screening and rates of operation may reduce differences in colorectal cancer outcomes for African-Americans.

13 Nov 2009

Data on BioAlliance Pharma's oral chemotherapy nanoparticle formulation presented at the AAPS meeting

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented its results on new oral chemotherapy nanoparticle formulation at the AAPS (American Association of Pharmaceutical Scientists) Annual Meeting in Los Angeles (November 8 to 12, 2009).

13 Nov 2009

AvidBiotics granted U.S. and European patents concerning its DGR technology platform

AvidBiotics Corp. announced the issuance of foundational patents encompassing a completely novel mechanism for generating massive diversity within precisely targeted sites of protein-encoding DNA sequences. The technology platform is referred to as Diversity Generating Retroelements (DGR) and patents were issued in both the United States (#7,585,957) and in Europe (#1,173,995). UCLA and AvidBiotics Corp are co-assignees of the patents, and AvidBiotics holds exclusive, worldwide rights to the patents from UCLA.

13 Nov 2009

UT Southwestern Medical Center awarded $42M for basic and patient-oriented research

UT Southwestern Medical Center has been awarded more than $42 million to date for basic and patient-oriented research from the American Recovery and Reinvestment Act of 2009, the $787 billion stimulus package President Barack Obama signed into law in February.

13 Nov 2009

Tips for preventing cancer

The risk of cancer can be dramatically reduced through everyday choices about diet, exercise and tobacco use, according to a Special Report on Cancer Prevention in the November issue of Mayo Clinic Women's HealthSource.

12 Nov 2009

Senesco's multiple myeloma drug candidate data to be presented at the AACR-NCI-EORTC conference

Senesco Technologies, Inc. announced today that Catherine Taylor, one of the Company's funded researchers, will be presenting pre-clinical stability and biological activity data on SNS-01, Senesco's multiple myeloma drug candidate, at the 2009 American Association for Cancer Research (AACR)-National Cancer Institute (NCI)-European Organization for Research and Treatment of Cancer (EORTC) Molecular Targets and Cancer Therapeutics Conference.

12 Nov 2009

Cequent Pharmaceuticals proposes the first test of an orally administered RNA interference drug in humans

Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, has announced that it has filed its first IND (investigational new drug) application with the U.S. Food and Drug Administration (FDA).

12 Nov 2009

Predictive power of Champions Biotechnology's Biomerk Tumorgraft platform to be presented

Champions Biotechnology, Inc., an oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, has announced that two of its studies regarding its application in oncology drug development and personalized medicine have been selected for a poster and oral presentation at the upcoming AACR-EORTC conference in Boston.

12 Nov 2009

Will the health bill bend costs?

One cause for health reform anxiety is that no one is sure whether the legislation would achieve one of its most critical goals: lowering health care costs.

12 Nov 2009

New Cat B 750 FAST imaging agent launched by VisEn Medical

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new Cat B 750 FAST(TM) imaging agent for measuring and monitoring cathepsin B activity associated with disease progression and therapeutic response in vivo. Cathepsin B expression is well known as a key biomarker and therapeutic target in a range of diseases, including atherosclerosis, oncology, and arthritis.

12 Nov 2009

Artificially increasing selenium status above the level required is unwarranted, study calls for further research

A new study from the University of Warwick has discovered taking too much of the essential mineral selenium in your diet can increase your cholesterol by almost 10%.

12 Nov 2009

Spectrum Pharmaceuticals reports consolidated revenues of $7.1M for the third quarter of 2009

Spectrum Pharmaceuticals, Inc., a commercial-stage biotechnology company with a primary focus in oncology, today reported financial results for the third quarter ended September 30, 2009.

12 Nov 2009

USPTO issues patent number to Vermillion's biomarkers for detecting ovarian cancer

Vermillion, Inc., a molecular diagnostics company, today announced that the U.S. Patent Office (USPTO) has issued patent number 7,605,003 titled "Use of biomarkers for detecting ovarian cancer" to the Company for the discovery of biomarkers for ovarian cancer.

12 Nov 2009

Arrayit Diagnostics develops diagnostic tests for early cancer detection

Arrayit Corporation announced today that the company's majority owned subsidiary, Arrayit Diagnostics, Inc., will launch the most intensive marketing campaign in the company's thirteen-year history. The company is currently developing several diagnostic tests that will provide early detection for cancers, neurodegenerative diseases and other disease states.

12 Nov 2009

Review of Mersana Therapeutics's lead compound, XMT-1001 to be published

Mersana Therapeutics, a platform-based cancer therapeutics company, announced today that a review of the Company's lead compound, XMT-1001, will appear in the November 12, 2009 special issue of Advanced Drug Delivery Reviews on Polymer Therapeutics: Clinical Applications and Challenges for Development.

12 Nov 2009

Bradmer Pharmaceuticals reports financial results for the third quarter of 2009

Bradmer Pharmaceuticals Inc. today announced its 2009 third quarter financial results.

12 Nov 2009

"Doctors Speak Out" series to discuss today's health issues

How can counting cancer cells in the blood make a difference in treatment? Can a potent hormone that fuels some breast cancers be used to fire back against the disease? These critical questions are being answered via innovative laboratory and clinical research underway at Georgetown Lombardi Comprehensive Cancer Center. A renowned pharmacologist who discovered a leading treatment for cancer and a physician treating patients in cutting edge clinical trials will discuss these and other life-enhancing discoveries during Doctors Speak Out, a series of conversations with physicians and researchers on today’s most pressing health issues.

12 Nov 2009

Pioneering cardiologist and inventor in heart medicine passed away

William Ganz, M.D., an internationally-recognized leader and inventor in heart medicine, died Tuesday night of natural causes. He was 90.

12 Nov 2009

Keryx Biopharmaceuticals to present KRX-0401 Phase 1/2 clinical trial data at the ASH meeting

Keryx Biopharmaceuticals, Inc. today announced that data from its Phase 1/2 clinical trial of KRX-0401 (perifosine) in combination with bortezomib (+/- dexamethasone) has been selected for poster presentation at the upcoming 51st Annual Meeting of the American Society of Hematology (ASH), to be held in New Orleans from December 5-8, 2009.

12 Nov 2009

Cancer News and Research

Latest Cancer News and Research

Varian and SSI sign reseller's agreement

African-Americans more likely to die from colorectal cancer than Caucasians, says new study

Data on BioAlliance Pharma's oral chemotherapy nanoparticle formulation presented at the AAPS meeting

AvidBiotics granted U.S. and European patents concerning its DGR technology platform

UT Southwestern Medical Center awarded $42M for basic and patient-oriented research

Tips for preventing cancer

Senesco's multiple myeloma drug candidate data to be presented at the AACR-NCI-EORTC conference

Cequent Pharmaceuticals proposes the first test of an orally administered RNA interference drug in humans

Predictive power of Champions Biotechnology's Biomerk Tumorgraft platform to be presented

Will the health bill bend costs?

New Cat B 750 FAST imaging agent launched by VisEn Medical

Artificially increasing selenium status above the level required is unwarranted, study calls for further research

Spectrum Pharmaceuticals reports consolidated revenues of $7.1M for the third quarter of 2009

USPTO issues patent number to Vermillion's biomarkers for detecting ovarian cancer

Arrayit Diagnostics develops diagnostic tests for early cancer detection

Review of Mersana Therapeutics's lead compound, XMT-1001 to be published

Bradmer Pharmaceuticals reports financial results for the third quarter of 2009

"Doctors Speak Out" series to discuss today's health issues

Pioneering cardiologist and inventor in heart medicine passed away

Keryx Biopharmaceuticals to present KRX-0401 Phase 1/2 clinical trial data at the ASH meeting

Understanding the DNA Damage Response in Innate Immunity eBook

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Newsletters you may be interested in